The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 01, 2022
Filed:
Sep. 20, 2018
Seoul National University R&db Foundation, Seoul, KR;
Postech Academy-industry Foundation, Gyeongsangbuk-do, KR;
Byeong Moon Kim, Seoul, KR;
Sung Key Jang, Gyeongsangbuk-do, KR;
Young Su You, Seoul, KR;
Il Hak Bae, Daegu, KR;
Heejo Moon, Gyeonggi-do, KR;
Byeong Wook Kim, Gyeongsangnam-do, KR;
Hee Sun Kim, Jeollanam-do, KR;
Jaegon Mun, Gyeongsangnam-do, KR;
Seoul National University R&DB Foundation, Seoul, KR;
Postech Academy-Industry Foundation, Gyeongsangbuk-Do, KR;
Abstract
The present invention relates to a fluorene derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition comprising the same as an effective ingredient for preventing or treating HCV-related disease. A fluorene derivative according to the present invention is identified to exhibit an antiviral performance against not only HCV, but also highly against HCV mutants, particularly double mutants and thus can be used in a pharmaceutical composition for prevention or treatment of HCV-caused liver disease, such as acute hepatitis C, chronic hepatitis C, liver cirrhosis, hepatocellular cancer, etc., particularly, liver disease caused by mutants of HCV. The derivative can be useful in a pharmaceutical composition for prevention or treatment of HCV-related liver disease by which the problem of resistant mutation against conventional therapeutic agents is solved.